RBC Capital analyst Douglas Miehm maintained a Buy rating on Oncolytics Biotech (ONCY) on March 11 and set a price target of C$6.00. The company’s shares closed last Friday at $2.99.
According to TipRanks.com, Miehm is a 1-star analyst with an average return of -0.2% and a 42.1% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Bausch Health Companies, and Medical Facilities.
Oncolytics Biotech has an analyst consensus of Strong Buy, with a price target consensus of $8.52, implying a 183.1% upside from current levels. In a report issued on March 8, Canaccord Genuity also maintained a Buy rating on the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.70 and a one-year low of $0.94. Currently, Oncolytics Biotech has an average volume of 1.67M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
